Rosetta Institute of biomedical Research

The Rosetta Institute of Biomedical Research is an independently funded medical research institute founded by Dr. Ryan Holzer, PhD.  The institute is funded by internally generated revenue, and by private donations.

We conduct basic and translational research on apoptosis in multiple myeloma and other malignancies, with the ultimate goal of identifying novel driver mutations responsible for tumorigenesis and the emergence of chemoresistant clones. Current research projects include:  1) discovering novel mechanisms of bortezomib (Velcade) resistance in multiple myeloma,  2) characterizing pro-apoptotic signaling pathways activated by Type 1 interferon (IFN-α/β),  3) the identification and characterization of ubiquitin ligases that regulate cell survival,  4) transcriptomic analysis and miRNA profiling of clonal evolution in cancer,  5) the discovery of novel roles for IL-6 family cytokines in hematologic malignancies,  6) The identification of novel alternatively spliced transcripts that contribute to tumor progression and the RNA-binding proteins that regulate rare exon inclusion/exclusion,  7) the role and regulation of autophagy during proteotoxic stress,  8)  adaptation to endoplasmic reticulum (ER) stress and mechanisms of ER stress-induced apoptosis,  9)  the identification and characterization of the multiple myeloma stem cell compartment and the bortezomib-resistant subclone, 10)  The role of hypoxia in drug sensitivity and clonal evolution.  A variety of techniques are being used at the Institute to address these questions, including bioinformatic analyses, CRISPR/Cas9 gene editing, tissue culture and mouse models of cancer.  Ultimately this knowledge will be translated into next generation therapeutics for the treatment of cancer and other diseases associated with splicing errors or disturbances in proteostasis.